Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 7/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112458 | 0.90 | CHRM3 (0.41) | FABP4FABP5CHRM3IDH2CHRM2 | |
| SCHEMBL5113237 | 0.89 | FABP4 (0.41) | FABP4FABP5KCNMA1IDH2LMNA | |
| SCHEMBL5100423 | 0.88 | CHRM3 (0.44) | FABP4FABP5CHRM3IDH2CHRM2 | |
| SCHEMBL5103316 | 0.87 | CHRM3 (0.43) | FABP4FABP5CHRM3IDH2CHRM2 | |
| SCHEMBL5113768 | 0.86 | KMT2A (0.42) | FABP4KCNMA1CHRM3LMNASMN1; SMN2 | |
| SCHEMBL5103918 | 0.86 | FABP4 (0.39) | FABP4FABP5CHRM3IDH2LMNA | |
| SCHEMBL3912448 | 0.84 | CHRM3 (0.50) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5112043 | 0.84 | CHRM3 (0.48) | CHRM3IDH2CHRM2CHRM1 | |
| SCHEMBL5103759 | 0.82 | CHRM3 (0.41) | KCNMA1CHRM3IDH2CHRM2CHRM1 | |
| SCHEMBL5099368 | 0.82 | CNR1 (0.43) | FABP4FABP5CHRM3IDH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | FABP4 4255/4885FABP5 1382/4885KCNMA1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.